Russian Scientific Center of Surgery named after Academician B.V. Petrovsky is conducting a clinical trial of gene-activated osteoplastic material for the treatment of patients with spine diseases. More than 200 patients have already been included in the study. A total of 300 patients will take part in the study. Gene-activated material for bone grafting was developed by Histograft, which is part of the Artgen Group. It has been used in clinical practice for bone grafting since 2020.